The Drug-Induced Cardiotoxicity Website and App

Dabrafenib-Trametinib combination therapy (BRAFi)

Frequency - Incidence

Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XXXVI.aa

Granulomatosis with polyangiitis (typically ANCA pos.) - GPA flare

Publications

Dimou A, Barron G, Merrick DT, Kolfenbach J, Doebele RC

Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma.

BMC cancer. 2020;20(1):177

Giraud V, Longvert C, Houlle-Crepin S, Danel C, Labrune S, Camus P, Saiag P, Chinet T

Relapsing pneumonitis due to two distinct inhibitors of the MAPK/ERK pathway: report of a case.

BMC cancer. 2015;15:732